Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of human breast cancer patients treated with Letrozole (Femara) early response to treatment


ABSTRACT: Tumorigenic breast cancer cells characterized by high CD44 and low or undetectable CD24 levels (CD44+/CD24-/low) may be resistant to conventional therapies and responsible for cancer relapse. We defined a “signature” expression pattern of hundreds of genes associated with CD44+/CD24-/low, mammosphere-forming cells. In a panel of patient breast tumors, this tumorigenic gene signature was found exclusively manifested in tumors of the recently identified “claudin-low” molecular profile subtype characterized by overexpression of many mesenchymal-associated genes, suggesting that these tumors have pre-existing higher levels of tumorigenic cells. Furthermore, when comparing the expression profiles of paired breast cancer core biopsies before versus after hormone therapy or chemotherapy, both the tumorigenic and “claudin-low” signatures were more active in about half of tumors after treatment, indicative of a greater enrichment of tumorigenic cells as a result of treatments targeting the bulk tumor cells. Experiment Overall Design: Biopsies were taken from the same subjects both pretreatment and after 10-14 days Letrozol, 2.5 mg/day, oral.

ORGANISM(S): Homo sapiens

SUBMITTER: Chad Creighton 

PROVIDER: E-GEOD-10281 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2009-08-15 | GSE10281 | GEO
2009-08-22 | E-GEOD-7513 | biostudies-arrayexpress
2009-08-15 | GSE7513 | GEO
2009-08-15 | GSE7515 | GEO
2009-08-22 | E-GEOD-7515 | biostudies-arrayexpress
2007-11-02 | E-GEOD-6883 | biostudies-arrayexpress
2009-04-01 | E-GEOD-10885 | biostudies-arrayexpress
2020-07-23 | PXD017789 | Pride
2009-04-01 | GSE10885 | GEO
2008-06-16 | E-GEOD-8828 | biostudies-arrayexpress